Moneycontrol » News » International Results

Daiichi Sankyo aims for 180 bn yen op profit in FY2012

Published on Fri, Mar 12, 2010 at 10:19 |  Source : Reuters

Updated at Fri, Mar 12, 2010 at 14:38  

Like this story, share it with millions of investors on M3
0
0
Share on Tumblr
Daiichi Sankyo aims for 180 bn yen op profit in FY2012

RELATED NEWS

ALSO READ

Daiichi Sankyo, Japan's third-largest drugmaker, said on Friday it is targeting an operating profit of 180 billion yen (USD 2 billion) on revenues of 1.15 trillion yen in the year to March 2013.
The firm also said it targets a return on equity of 10% or more and earnings per share of 140 yen or more in that financial year, against 5.2% and 63.9 yen estimated for the current year.
The company, which bought a majority stake in India's Ranbaxy Laboratories in 2008 to diversify its operations into generic drugs and emerging markets, said it expects overseas operations to account for 650 billion yen of the targeted overall revenue.
For the current year ending on March 31, the company has forecast an operating profit of 96 billion yen on revenues of 960 billion yen.
Analysts on average expect Daiichi Sankyo to generate an operating profit of 124.5 billion yen on revenues of 1.03 trillion yen in the year to March 2012, according to a poll by Thomson Reuters I/B/E/S.
Daiichi Sankyo president Takashi Shoda will give a briefing on the company's mid-term business plan later on Friday.

  

Trending News

Business News

Tags: daiichi
2TB drives offer best value for money
Did Sebi miss any tricks in Ambani consent order? "Did Sebi miss any tricks in Ambani consent order?"

Oppn gears up to make Bharat bandh a success

On Facebook IPO Morgan Stanley Speculation Of 'Nefarious Activity' Around IPO Untrue

The latest earning numbers FIRST on CNBC-TV18
Videos

May 30 2012, 23:16

Clash of Spain and ECB worrying investors: Verstrate

- in FII View

May 30 2012, 11:18

Result corner: Ajay Bodke`s top bets from across sectors

- in MARKET OUTLOOK

Interviews

May 30 2012, 17:04 | Source: CNBC-TV18

Margins may be hit on one-off items in EBITDA: Sun Pharma  

May 30 2012, 16:32 | Source: CNBC-TV18

Essar announces Rs 175cr deal; to pay-off debts with fund  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!